GPC Biotech AG
GPC Biotech AG is a public biopharmaceutical company discovering, developing and commercializing new anticancer drugs. The Company's lead product candidate Satraplatin is currently under review by the U.S. FDA for hormone-refractory prostate cancer patients. Several other candidates are near and in Phase 1 clinical testing. GPC Biotech AG is headquartered in Martinsried/Munich (Germany) with a wholly owned U.S. subsidiary in Princeton, NJ.
Human Resources Dept.